摘要
中毒性表皮坏死松解症(Toxic epidermal necrolysis,TEN)是一种严重威胁人类生命的疾病。本文报道1例由第3代表皮生长因子受体(Epidermal growth factor receptor,EGFR)酪氨酸激酶抑制剂(Tyrosine kinase inhibitor,TKI)-奥希替尼导致的TEN。患者为58岁女性,因左肺鳞癌伴脑转移、骨转移、EGFR19外显子非移码缺失性突变,口服奥希替尼。服药约14 d后,患者颈部、胸部首先出现红斑,伴明显瘙痒,后皮损进行性加重,逐渐扩散至头部、面部、躯干、四肢及外阴部,并出现水疱、大疱及表皮剥脱,剥脱面积约占体表面积的60%。治疗上,停用奥希替尼,全身使用糖皮质激素、免疫球蛋白、防治感染及对症支持治疗,同时予精心的创面护理。住院26 d后患者症状好转出院。
Toxic epidermal necrolysis(TEN) is a disease that seriously threatens human life.A case of TEN is reported,which is induced by the third epidermal growth factor receptor(EGFR) tyrosine-kinase inhibitor(TKI)-osimertinib.The patient was a 58-year-old female with left lung squamous cell carcinoma complicated with brain metastases,bone metastases,and EGFR 19 exon non-frameshift deletion mutations,who received oral osimertinib.About 14 days after taking the medicine,the patient first developed erythema on the neck and chest,accompanied by obvious pruritus,and later there was a progressive aggravation of the skin lesion,involving the head,face,trunk,limbs and vulva.The skin appeared blister,bullae and epidermal exfoliation,and the exfoliation area reached 60% of body surface area.Osimertinib was stopped.The patient was treated with glucocorticoid and immunoglobulin,and received prevention of infection and symptomatic support therapy along with meticulous wound care.After 26 days of hospitalization,the patient was discharged with symptoms improved.
作者
刘秀坤
马雷
陈雷
沈芳
Liu Xiukun;Ma Lei;Chen Lei;Shen Fang(Department of Pharmacy,Second Affiliated Hospital of Xuzhou Medical University,Xuzhou 221000,China;Department of Respiratory and Critical Medicine,Second Affiliated Hospital of Xuzhou Medical University,Xuzhou 221000,China)
出处
《实用药物与临床》
CAS
2022年第10期958-960,共3页
Practical Pharmacy and Clinical Remedies
